{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:25:08Z","timestamp":1793384708770,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.adro.2022.100948","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T03:27:18Z","timestamp":1647833238000},"page":"100948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Outcomes of Patients With Unresectable Primary Liver Cancer Treated With Yttrium-90 Radioembolization With an Escalated Dose"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2642-5712","authenticated-orcid":false,"given":"Re-I","family":"Chin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh","family":"Bommireddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Fraum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline E.","family":"Zoberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Garcia-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichole M.","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Korenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Henke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6243-526X","authenticated-orcid":false,"given":"Shahed N.","family":"Badiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2022.100948_bib0001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.adro.2022.100948_bib0002","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00000658-198510000-00001","article-title":"Role of liver transplantation in cancer therapy","volume":"202","author":"Iwatsuki","year":"1985","journal-title":"Annal Surg"},{"key":"10.1016\/j.adro.2022.100948_bib0003","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1002\/1097-0142(19810501)47:9<2162::AID-CNCR2820470909>3.0.CO;2-5","article-title":"The seventies evolution in liver surgery for cancer","volume":"47","author":"Fortner","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2022.100948_bib0004","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1245\/s10434-008-0071-3","article-title":"Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation","volume":"15","author":"Heckman","year":"2008","journal-title":"Annal Surg Oncol"},{"key":"10.1016\/j.adro.2022.100948_bib0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.adro.2022.100948_bib0006","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1051-0443(07)61790-4","article-title":"Yttrium-90 microspheres: Radiation therapy for unresectable liver cancer","volume":"13","author":"Salem","year":"2002","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0007","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1055\/s-2006-939842","article-title":"Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver","volume":"23","author":"Lewandowski","year":"2006","journal-title":"Sem Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","article-title":"Radioembolization of hepatic malignancies: Background, quality improvement guidelines, and future directions","volume":"28","author":"Padia","year":"2017","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0009","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00259-019-04340-5","article-title":"Clinical and dosimetric considerations for Y90: Recommendations from an international multidisciplinary working group","volume":"46","author":"Salem","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.adro.2022.100948_bib0010","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jvir.2018.03.018","article-title":"Radioembolization for hepatocellular carcinoma: A nationwide 10-year experience","volume":"29","author":"Tohme","year":"2018","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0011","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.29691","article-title":"Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience","volume":"68","author":"Salem","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.adro.2022.100948_bib0012","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","article-title":"Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option","volume":"17","author":"Saxena","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.adro.2022.100948_bib0013","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jvir.2013.02.031","article-title":"Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: Safety, response, and survival analysis","volume":"24","author":"Mouli","year":"2013","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0014","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jvir.2018.04.001","article-title":"Intrahepatic cholangiocarcinoma treated with transarterial yttrium-90 glass microsphere radioembolization: Results of a single institution retrospective study","volume":"29","author":"Gangi","year":"2018","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0015","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00270-017-1648-7","article-title":"Yttrium-90 radioembolization for unresectable combined hepatocellular-cholangiocarcinoma","volume":"40","author":"Chan","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0016","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jvir.2019.09.028","article-title":"Outcomes of yttrium-90 radioembolization for unresectable combined biphenotypic hepatocellular-cholangiocarcinoma","volume":"31","author":"Malone","year":"2020","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0017","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.adro.2022.100948_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00210","article-title":"Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective","volume":"4","author":"Cremonesi","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2022.100948_bib0019","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2020.38.4_suppl.516","article-title":"Major impact of personalized dosimetry using 90Y loaded glass microspheres SIRT in HCC: Final overall survival analysis of a multicenter randomized phase II study (DOSISPHERE-01)","volume":"38","author":"Garin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100948_bib0020","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation segmentectomy: Potential curative therapy for early hepatocellular carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.adro.2022.100948_bib0021","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/hep.27057","article-title":"Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology-pathology correlation and survival of radiation segmentectomy","volume":"60","author":"Vouche","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.adro.2022.100948_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jimed.2019.05.001","article-title":"Radiation segmentectomy for hepatic malignancies: Indications, devices, dosimetry, procedure, clinical outcomes, and toxicity of yttrium-90 microspheres","volume":"2","author":"Jia","year":"2019","journal-title":"J Intervent Med"},{"key":"10.1016\/j.adro.2022.100948_bib0023","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.RVI.0000164324.79242.B2","article-title":"Angiographic considerations in patients undergoing liver-directed therapy","volume":"16","author":"Liu","year":"2005","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0024","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijrobp.2006.11.060","article-title":"Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the Radioembolization Brachytherapy Oncology Consortium","volume":"68","author":"Kennedy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.100948_bib0025","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jvir.2016.12.1221","article-title":"Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: A retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography\/CT","volume":"28","author":"Haste","year":"2017","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0026","series-title":"MIRD Primer for Absorbed Dose Calculations","author":"Loevinger","year":"1991"},{"key":"10.1016\/j.adro.2022.100948_bib0027","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jvir.2008.02.002","article-title":"C-arm cone-beam CT: General principles and technical considerations for use in interventional radiology","volume":"19","author":"Orth","year":"2008","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0028","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jvir.2009.01.021","article-title":"Incorporating cone-beam CT into the treatment planning for yttrium-90 radioembolization","volume":"20","author":"Louie","year":"2009","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0029","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed March 15, 2022."},{"key":"10.1016\/j.adro.2022.100948_bib0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.adro.2022.100948_bib0031","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hep.27915","article-title":"Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma","volume":"62","author":"Seyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.adro.2022.100948_bib0032","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jvir.2014.03.030","article-title":"Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity","volume":"25","author":"Padia","year":"2014","journal-title":"J Vasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0033","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/tri.13153","article-title":"Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients, a multicentre cohort study","volume":"31","author":"Manzia","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.adro.2022.100948_bib0034","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0360-3016(02)02864-X","article-title":"Dose-response relationship in local radiotherapy for hepatocellular carcinoma","volume":"54","author":"Park","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.100948_bib0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): A randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.adro.2022.100948_bib0036","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijrobp.2018.05.062","article-title":"Hepatocellular carcinoma tumor dose response after 90 y-radioembolization with glass microspheres using 90 Y-SPECT\/CT-based voxel dosimetry","volume":"102","author":"Kappadath","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.100948_bib0037","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijrobp.2018.01.116","article-title":"Prospective trial using internal pair-production positron emission tomography to establish the yttrium-90 radioembolization dose required for response of hepatocellular carcinoma","volume":"101","author":"Chan","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.100948_bib0038","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/MNM.0000000000000887","article-title":"Correlation of radiation dose and activity with clinical outcomes in metastatic colorectal cancer after selective internal radiation therapy using yttrium-90 resin microspheres","volume":"39","author":"Badiyan","year":"2018","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.adro.2022.100948_bib0039","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: The LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.adro.2022.100948_bib0040","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","article-title":"Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: Confirmatory multicenter analysis in 45 explants","volume":"48","author":"Gabr","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.adro.2022.100948_bib0041","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","article-title":"Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: Factors associated with prolonged survival","volume":"35","author":"Hoffmann","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.adro.2022.100948_bib0042","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.adro.2019.08.003","article-title":"Stereotactic body radiation therapy for cholangiocarcinoma: Optimizing locoregional control with elective nodal irradiation","volume":"5","author":"Kozak","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2022.100948_bib0043","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ijrobp.2017.06.2467","article-title":"Prognostic factors and patterns of locoregional failure after surgical resection in patients with cholangiocarcinoma without adjuvant radiation therapy: Optimal field design for adjuvant radiation therapy","volume":"99","author":"Ghiassi-Nejad","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.100948_bib0044","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s12094-015-1312-0","article-title":"Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: Implications for adjuvant radiotherapy","volume":"17","author":"Song","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.adro.2022.100948_bib0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijrobp.2009.10.062","article-title":"Radiation segmentectomy: A novel approach to increase safety and efficacy of radioembolization","volume":"79","author":"Riaz","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:39:58Z","timestamp":1762529998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109422000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2452109422000550"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2022.100948","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Patients With Unresectable Primary Liver Cancer Treated With Yttrium-90 Radioembolization With an Escalated Dose","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2022.100948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100948"}}